Eli Lilly Just Had a Setback. Is Its Stock Still a Buy?

Mar 16, 2024 · In 2023, Eli Lilly had $34.1 billion in revenue.On average, analysts see its top line growing to $45 billion in 2025, of which $837 million is expected to be attributable to sales of …

$34
OFF

Eli Lilly Just Had A Setback. Is Its Stock Still A Buy?

2 weeks from now

fool.com

$34
OFF

Eli Lilly Just Had A Setback. Is Its Stock Still A Buy? - Yahoo Finance

2 weeks from now

yahoo.com

20%
OFF

Eli Lilly Just Hit A Milestone That Disappointed. Here's Why You …

2 weeks from now

Nov 8, 2024 · During Q3, Eli Lilly brought in $11.4 billion in sales, up 20% from a year prior, and non-GAAP (adjusted) EPS of $1.18, which was $0.29 less than what the average of Wall …

yahoo.com

58%
OFF

Up 58% YTD, Is Eli Lilly Stock Still A Buy? - Nasdaq

2 weeks from now

Aug 19, 2024 · The Street-high price target of $1,117 suggests that Eli Lilly stock could rise as much as 21.4% from here. At nearly 58x forward adjusted earnings, LLY stock is definitely …

nasdaq.com

20%
OFF

Down More Than 20% From Its High, Is Now The Time To Buy Eli …

2 weeks from now

Nov 28, 2024 · Eli Lilly (LLY 1.61%) is the most valuable healthcare stock in the world, with a market capitalization of nearly $700 billion. But in recent weeks, its share price has been …

fool.com

$34
OFF

Eli Lilly Just Had A Setback. Is Its Stock Still A Buy?

2 weeks from now

Mar 16, 2024 · In 2023, Eli Lilly had $34.1 billion in revenue. On average, analysts see its top line growing to $45 billion in 2025, of which $837 million is expected to be attributable to sales of …

theglobeandmail.com

10%
OFF

Eli Lilly Falls More Than 10% In A Month: Buy, Sell Or Hold The Stock?

2 weeks from now

Nov 11, 2024 · Lilly’s stock has risen 42.7% so far this year compared with an increase of 11.6% for the industry. The stock has also outperformed the sector as well as the S&P 500, as seen …

nasdaq.com

20%
OFF

Eli Lilly Just Got A Bundle Of Good News: Time To Buy?

2 weeks from now

Dec 4, 2024 · Plenty of reasons to buy. Eli Lilly's shares recently dropped after its third-quarter results did not meet expectations. The company's revenue increased by 20% year over year to …

fool.com

$540
OFF

After Earnings, Is Eli Lilly Stock A Buy, A Sell, Or Fairly Valued?

2 weeks from now

May 13, 2024 · Fair Value Estimate for Eli Lilly Stock. With its 2-star rating, we believe Eli Lilly’s stock is overvalued compared with our long-term fair value estimate of $540.

morningstar.com

17%
OFF

Eli Lilly Stock: 4 Reasons To Buy The Dip After A 17% Drop

2 weeks from now

1 day ago · Eli Lilly stock is down 17.75% from its highs as of Jan 10, 2025, even after authorizing a 15 billion stock buyback program. Sales of its GLP-1 drug, Mounjaro, surged 129% YoY in …

marketbeat.com

5%
OFF

Eli Lilly Shares Down 7.5% As Market Reacts To Slashed Q4 Forecast

2 weeks from now

16 hours ago · Shares of Eli Lilly are down 7.6% today, reflecting market disappointment in the company's adjusted guidance for the fourth quarter of 2024.The pharmaceutical giant expects …

yahoo.com

$45
OFF

Eli Lilly: Still Expensive As Earnings Near, But Not Worthy Of A ...

2 weeks from now

3 days ago · Eli Lilly and Company. When it comes to the 2024 fiscal year in its entirety, management expects revenue to be between $45.4 billion and $46 billion. Even though this is …

seekingalpha.com

FAQs about Eli Lilly Just Had a Setback. Is Its Stock Still a Buy? Coupon?

Is Eli Lilly (LLY) a good stock to buy?

Solid growth prospects, however, could propel the business a lot higher. Eli Lilly (LLY 0.91%) is the most valuable healthcare stock in the world, with a market capitalization of nearly $700 billion. But in recent weeks, its share price has been falling. And now the stock is down over 20% from its 52-week high of $972.53. ...

Why has Eli Lilly stock rallied 30% this year?

Eli Lilly’s LLY stock has rallied 30% this year due to optimism about two potential new product lines. The key drivers of the rally in Eli Lilly stock are the potential for two of the company’s drugs: Mounjaro (tirzepatide) for weight loss and donanemab for early Alzheimer’s. ...

Is Eli Lilly still a buy?

So Eli Lilly is still a buy, and the latest news about donanemab doesn't change anything about that fact. Alex Carchidi has no position in any of the stocks mentioned. The Motley Fool recommends Biogen. The Motley Fool has a disclosure policy. ...

Why are Eli Lilly shares down 76% today?

Shares of Eli Lilly (NYSE:LLY) are down 7.6% today, reflecting market disappointment in the company's adjusted guidance for the fourth quarter of 2024. The pharmaceutical giant expects only $13.5 billion in revenue for Q4 2024, compared to the consensus estimate of $13.97 billion. ...

How much money will Eli Lilly make in 2023?

In 2023, Eli Lilly had $34.1 billion in revenue. On average, analysts see its top line growing to $45 billion in 2025, of which $837 million is expected to be attributable to sales of donanemab, or approximately 1.8% of total revenue. That's hardly an amount of sales to lose any sleep over. ...

Should you invest in Eli Lilly?

One of Eli Lilly's potential competitors in the weight loss market just reported unimpressive trial results. The company could benefit from the government coverage of its weight loss medicines. There is still a great argument for investing in Eli Lilly. The magic isn't over for Eli Lilly (LLY -2.80%). ...